###begin article-title 0
Phase I Metabolic Genes and Risk of Lung Cancer: Multiple Polymorphisms and mRNA Expression
###end article-title 0
###begin p 1
Conceived and designed the experiments: DC ACP AMG LG SW PAB MT NEC AWB MTL. Performed the experiments: RW LB SJC. Analyzed the data: MR KY JL SW NC AWB. Contributed reagents/materials/analysis tools: DC ACP PAB MT NEC MTL. Wrote the paper: MR MTL. Reviewed the manuscript: KY JL DC AMG LG SW RW LB SJC PAB MT NEC NC AWB.
###end p 1
###begin p 2
###xml 995 1000 995 1000 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EPHX1</italic>
###xml 1093 1099 1093 1099 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP1B1</italic>
###xml 1104 1110 1104 1110 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2A6</italic>
###xml 1253 1259 1253 1259 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP1A1</italic>
###xml 1448 1457 1448 1457 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP1A1/A2</italic>
###xml 1651 1657 1651 1657 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP1A1</italic>
###xml 1709 1718 1709 1718 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP1A1/A2</italic>
###xml 56 63 <span type="species:ncbi:4097">tobacco</span>
Polymorphisms in genes coding for enzymes that activate tobacco lung carcinogens may generate inter-individual differences in lung cancer risk. Previous studies had limited sample sizes, poor exposure characterization, and a few single nucleotide polymorphisms (SNPs) tested in candidate genes. We analyzed 25 SNPs (some previously untested) in 2101 primary lung cancer cases and 2120 population controls from the Environment And Genetics in Lung cancer Etiology (EAGLE) study from six phase I metabolic genes, including cytochrome P450s, microsomal epoxide hydrolase, and myeloperoxidase. We evaluated the main genotype effects and genotype-smoking interactions in lung cancer risk overall and in the major histology subtypes. We tested the combined effect of multiple SNPs on lung cancer risk and on gene expression. Findings were prioritized based on significance thresholds and consistency across different analyses, and accounted for multiple testing and prior knowledge. Two haplotypes in EPHX1 were significantly associated with lung cancer risk in the overall population. In addition, CYP1B1 and CYP2A6 polymorphisms were inversely associated with adenocarcinoma and squamous cell carcinoma risk, respectively. Moreover, the association between CYP1A1 rs2606345 genotype and lung cancer was significantly modified by intensity of cigarette smoking, suggesting an underling dose-response mechanism. Finally, increasing number of variants at CYP1A1/A2 genes revealed significant protection in never smokers and risk in ever smokers. Results were supported by differential gene expression in non-tumor lung tissue samples with down-regulation of CYP1A1 in never smokers and up-regulation in smokers from CYP1A1/A2 SNPs. The significant haplotype associations emphasize that the effect of multiple SNPs may be important despite null single SNP-associations, and warrants consideration in genome-wide association studies (GWAS). Our findings emphasize the necessity of post-GWAS fine mapping and SNP functional assessment to further elucidate cancer risk associations.
###end p 2
###begin title 3
Introduction
###end title 3
###begin p 4
###xml 193 196 193 196 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005652-Jemal1">[1]</xref>
###xml 326 329 326 329 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005652-Wright1">[2]</xref>
###xml 623 626 623 626 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005652-Shields1">[3]</xref>
###xml 797 800 797 800 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005652-Gresner1">[4]</xref>
###xml 882 885 882 885 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005652-Kiyohara1">[5]</xref>
###xml 198 205 <span type="species:ncbi:4097">Tobacco</span>
###xml 435 442 <span type="species:ncbi:4097">tobacco</span>
Lung cancer is the second most common malignancy and has the highest cancer mortality rate worldwide, with an estimated 161,840 individuals expected to succumb to the disease in 2008 in the US [1]. Tobacco smoking is the dominant causal factor for lung cancer; however, fewer than 20% of cigarette smokers develop the disease [2], suggesting that inherited genetic factors may also be important risk determinants. Genetic variation at tobacco carcinogen metabolizing enzymes may lead to inter-individual differences in the level of internal carcinogenic dose and to differential risk for individuals with similar exposures [3]. For this reason, genes that encode enzymes activating harmful chemicals are suitable candidates for lung cancer susceptibility studies and have been intensively studied [4]. Nevertheless, the available published data generally offer inconsistent results [5], due to population heterogeneity, low sample size, poor characterization of the exposure, and a few polymorphisms tested with low power to address the presence of their joint effects.
###end p 4
###begin p 5
###xml 284 287 284 287 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005652-Landi1">[6]</xref>
Here we addressed these issues in the analysis of candidate genes in phase I metabolism and lung cancer susceptibility, taking advantage of a large sample size and detailed epidemiological and clinical information of the Environment And Genetics in Lung cancer Etiology (EAGLE) study [6]. Furthermore, we integrated results on polymorphisms with data on expression from the same genes and the same subjects, for the first time in the context of a population study of phase I metabolic genes and lung cancer.
###end p 5
###begin p 6
###xml 175 181 175 181 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP1B1</italic>
###xml 183 189 183 189 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP1A1</italic>
###xml 191 197 191 197 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP1A2</italic>
###xml 203 209 203 209 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2A6</italic>
###xml 242 247 242 247 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EPXH1</italic>
###xml 271 274 271 274 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MPO</italic>
We explored the role of 25 single nucleotide polymorphisms (SNPs) covering important genes involved in the activation of carcinogens from cigarette smoking: cytochrome P450s (CYP1B1, CYP1A1, CYP1A2, and CYP2A6), microsomal epoxide hydrolase (EPXH1), and myeloperoxidase (MPO). We included also SNPs not previously analyzed, thus providing wide loci coverage in areas previously understudied.
###end p 6
###begin title 7
Candidate genes
###end title 7
###begin p 8
###xml 114 117 114 117 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005652-Hoffmann1">[7]</xref>
###xml 157 160 157 160 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005652-Shimada1">[8]</xref>
###xml 453 472 453 472 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cytochrome P450 1A1</bold>
###xml 474 480 474 480 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP1A1</italic>
###xml 486 505 486 505 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cytochrome P450 1B1</bold>
###xml 507 513 507 513 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP1B1</italic>
###xml 610 615 610 615 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EPHX1</italic>
###xml 703 709 703 709 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP1B1</italic>
###xml 762 765 762 765 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005652-Kim1">[9]</xref>
###xml 815 821 815 821 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP1A1</italic>
###xml 826 832 826 832 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP1B1</italic>
###xml 945 949 945 949 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005652-Spink1">[10]</xref>
###xml 951 955 951 955 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005652-Spivack1">[11]</xref>
###xml 984 990 984 990 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP1A1</italic>
###xml 995 1001 995 1001 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP1B1</italic>
###xml 1147 1151 1147 1151 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005652-Nebert1">[12]</xref>
###xml 1170 1176 1170 1176 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP1A1</italic>
###xml 1249 1253 1249 1253 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005652-Tefre1">[13]</xref>
###xml 1254 1258 1254 1258 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005652-Shah1">[17]</xref>
###xml 1530 1534 1530 1534 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005652-Alexandrov1">[18]</xref>
###xml 1594 1600 1594 1600 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP1A1</italic>
###xml 1608 1627 1608 1627 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cytochrome P450 1A2</bold>
###xml 1629 1635 1629 1635 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP1A2</italic>
###xml 1679 1683 1679 1683 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005652-Ueda1">[19]</xref>
###xml 1720 1729 1720 1729 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP1A1/A2</italic>
###xml 1913 1917 1913 1917 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005652-Hung1">[20]</xref>
###xml 1918 1922 1918 1922 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005652-Wang1">[24]</xref>
###xml 1928 1934 1928 1934 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP1B1</italic>
###xml 2257 2261 2257 2261 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005652-Hanna1">[25]</xref>
###xml 2335 2339 2335 2339 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005652-Aklillu1">[26]</xref>
###xml 2381 2387 2381 2387 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP1B1</italic>
###xml 2459 2463 2459 2463 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005652-Cote1">[27]</xref>
###xml 2464 2468 2464 2468 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005652-Zienolddiny1">[30]</xref>
###xml 2492 2498 2492 2498 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP1B1</italic>
###xml 2572 2600 2572 2600 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Microsomal epoxide hydrolase</bold>
###xml 2602 2607 2602 2607 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EPHX1</italic>
###xml 2958 2963 2958 2963 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">trans</italic>
###xml 2982 2986 2982 2986 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005652-Oesch1">[31]</xref>
###xml 3175 3179 3175 3179 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005652-Fretland1">[32]</xref>
###xml 3181 3185 3181 3185 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005652-Seidegard1">[33]</xref>
###xml 3187 3192 3187 3192 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EPHX1</italic>
###xml 3348 3352 3348 3352 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005652-Coller1">[34]</xref>
###xml 3431 3436 3431 3436 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EPHX1</italic>
###xml 3642 3646 3642 3646 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005652-Hassett1">[35]</xref>
###xml 3647 3651 3647 3651 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005652-Zhu1">[37]</xref>
###xml 3714 3719 3714 3719 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EPHX1</italic>
###xml 3885 3891 3885 3891 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al.</italic>
###xml 3908 3912 3908 3912 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005652-Kiyohara2">[38]</xref>
###xml 3940 3944 3940 3944 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005652-Graziano1">[39]</xref>
###xml 3946 3950 3946 3950 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005652-Voho1">[40]</xref>
###xml 4065 4084 4065 4084 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cytochrome P450 2A6</bold>
###xml 4086 4092 4086 4092 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2A6</italic>
###xml 4231 4235 4231 4235 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005652-Lewis1">[41]</xref>
###xml 4250 4256 4250 4256 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2A6</italic>
###xml 4363 4367 4363 4367 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005652-Nakajima1">[42]</xref>
###xml 4569 4573 4569 4573 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005652-London1">[43]</xref>
###xml 4574 4578 4574 4578 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005652-Kamataki1">[45]</xref>
###xml 4611 4617 4611 4617 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2A6</italic>
###xml 4692 4695 4692 4695 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Leu</italic>
###xml 4699 4702 4699 4702 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">His</italic>
###xml 4818 4822 4818 4822 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005652-Pianezza1">[46]</xref>
###xml 4867 4882 4867 4882 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Myeloperoxidase</bold>
###xml 4884 4887 4884 4887 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MPO</italic>
###xml 5005 5009 5005 5009 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005652-Schmekel1">[47]</xref>
###xml 5031 5035 5031 5035 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005652-Mallet1">[48]</xref>
###xml 5063 5067 5063 5067 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005652-Kadlubar1">[49]</xref>
###xml 5124 5128 5124 5128 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005652-Trush1">[50]</xref>
###xml 5193 5196 5193 5196 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MPO</italic>
###xml 5288 5292 5288 5292 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005652-VanSchooten1">[51]</xref>
###xml 5352 5355 5352 5355 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MPO</italic>
###xml 5389 5393 5389 5393 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005652-Feyler1">[52]</xref>
###xml 5487 5491 5487 5491 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005652-Xu1">[53]</xref>
###xml 5541 5544 5541 5544 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MPO</italic>
###xml 36 43 <span type="species:ncbi:4097">tobacco</span>
###xml 316 321 <span type="species:ncbi:9606">human</span>
###xml 401 408 <span type="species:ncbi:4097">tobacco</span>
###xml 871 876 <span type="species:ncbi:9606">human</span>
###xml 957 964 <span type="species:ncbi:4097">Tobacco</span>
###xml 4059 4064 <span type="species:ncbi:9606">human</span>
###xml 4960 4965 <span type="species:ncbi:9606">human</span>
###xml 5071 5078 <span type="species:ncbi:4097">tobacco</span>
Many of the chemical carcinogens in tobacco smoke are members of the polycyclic aromatic hydrocarbon (PAH) family [7]. Cytochrome P450 enzymes activate PAHs [8] to epoxide intermediates, which are converted by epoxide hydrolase to the carcinogens diol-epoxides that interact with DNA or proteins to form adducts. In human lung for example, Benzo[a]pyrene (B[a]P) - a major carcinogenic constituent in tobacco smoke - is first metabolically activated by cytochrome P450 1A1 (CYP1A1) and cytochrome P450 1B1 (CYP1B1) to form B[a]P-7,8-dihydroepoxide, which is further hydrolyzed by microsomal epoxide hydrolase (EPHX1) to (F)-benzo[a] pyrene-trans-7,8-dihydrodiol. This compound is further metabolized by CYP1B1 to form benzo[a]pyrene-7,8-dihydrodiol-9,10-epoxide [9], the most mutagenic and carcinogenic metabolite. CYP1A1 and CYP1B1 are over expressed in a wide range of human cancers, including breast, colon, lung, brain and testicular cancer [10], [11]. Tobacco smoking can induce CYP1A1 and CYP1B1 proteins up to 10-fold higher levels, particularly in subjects (about 10% of the general population) that are more sensitive to enzyme induction [12]. Polymorphisms in CYP1A1 (chr15q24.1) are the most frequently studied in relation to lung cancer [13]-[17], but results are limited to only a few SNPs (rs4646903, rs1048943, and rs1799814) that are more frequent in Asian than in Caucasian populations. Functional studies for these SNPs have predicted an increased catalytic activity and higher levels of hydrophobic DNA adducts [18]. In close proximity and strong linkage disequilibrium with CYP1A1 is the cytochrome P450 1A2 (CYP1A2) gene, characterized by a similar activity [19]. Our study included 8 SNPs from the CYP1A1/A2 region not previously studied in case-control studies of lung cancer, and some of these SNPs were not included in the platforms used for recent genome-wide association studies (GWAS) [20]-[24]. The CYP1B1 gene is located on chr2p22.2 and characterized by at least 178 SNPs (ncbi.nlm.nih.gov/dbSNP), including 4 common SNPs that encode amino acid substitutions at codons 48, 119, 432, and 435. These four common amino acid variants alter catalytic activity depending on the substrate, e.g., increase for estradiol hydroxylation [25] and decrease for B[a]P epoxidation and phenylimidazo-pyridine metabolism [26]. Relatively few studies have reported on CYP1B1 polymorphisms and lung cancer susceptibility with inconsistent results [27]-[30]. We selected 7 SNPs in CYP1B1 gene, 6 of which not previously studied in association with lung cancer. Microsomal epoxide hydrolase (EPHX1 gene, chr1q42.12) plays a dual role in the metabolism of PAHs and other environmental pollutants, detoxification and bioactivation depending on the substrate. It hydrolyzes reactive compounds such as arene, alkene, and aliphatic epoxides, which are generated by cytochrome P450 and other phase I enzymes to the corresponding dihydrodiols through the trans addition of water [31]. On the other hand, less reactive dihydrodiols from PAHs can be substrates for further transformation into dihydrodiol-epoxides such as the carcinogen benzo[a]pyrene-7,8-diol-9,10 epoxide [32], [33]. EPHX1 appears to be expressed in all tissues but the highest concentrations have been found in the liver, gonads, kidneys, lungs, and bronchial epithelial cells [34]. According to the NCBI's dbSNP database, 119 SNPs have been identified in the EPHX1 gene region, 20 of which are part of the HapMap database. Functional expression studies are available on a limited number of these polymorphisms and showed effects on hydrolase activity in both directions [35]-[37]. Few studies have investigated the association between coding EPHX1 polymorphisms and lung cancer susceptibility, with disparate findings mainly limited to the two non-synonymous SNPs rs1051740 and rs2234922, as reported by Kiyohara et al. in their review [38] and in more recent studies [39], [40]. We included 8 SNPs from EPHX1 gene, 7 of which not previously studied in association with lung cancer. The human cytochrome P450 2A6 (CYP2A6) is responsible for the metabolism of different exogenous compounds including nitrosamines, aflatoxin B1, and other xenobiotic substrates [41]. In addition, CYP2A6 catalyzes nicotine C-oxidation to cotinine, and the subsequent hydroxylation of cotinine to 3-OH-cotinine [42]. Several genetic polymorphisms including point mutations and deletions have been reported and studied in association with lung cancer with conflicting results in populations from different ethnicities [43]-[45]. In particular the polymorphism CYP2A6 rs1801272 selected for this study, which causes an amino acid change from Leu to His, has been object of dispute: studies found a protective association with lung cancer and amount of cigarette smoke [46] which has not been consistently replicated. Myeloperoxidase (MPO gene, chr17q22) is a lysosomal enzyme present in high concentrations in human lung due to recruitment of neutrophils [47], and activates B[a]P [48] as well as aromatic amines [49] in tobacco smoke and generates carcinogen-free radicals [50]. A single base substitution, -463G>A, in the promoter region of MPO reduces transcription activity and DNA adduct levels in bronchoalveolar lavages of smokers [51]. These mechanisms have supported protective effects of the MPO -463A allele against lung cancer [52]. However, this possible inverse association with lung cancer risk has remained controversial [53]. Therefore, further study of the effects of this MPO polymorphism on lung cancer is warranted, and we included this SNP in our selection.
###end p 8
###begin p 9
###xml 593 597 593 597 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005652-Lubin1">[54]</xref>
###xml 1531 1539 1529 1537 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">a priori</italic>
###xml 1623 1627 1621 1625 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005652-Wacholder1">[55]</xref>
###xml 122 129 <span type="species:ncbi:4097">tobacco</span>
###xml 213 220 <span type="species:ncbi:4097">tobacco</span>
A precise characterization of the smoking exposure is essential to successfully identify molecular mechanisms involved in tobacco-related lung carcinogenesis. The EAGLE study provides detailed characterization of tobacco smoking including quantitative information on total exposure and daily intake of cigarette smoking. Using this information, we evaluated genotype-smoking interactions by likelihood ratio test, and compared the contributions of total exposure (pack-years) and intensity (cigarettes per day) of smoking using the linear-exponential model for smoking excess odds ratio (EOR) [54]. This model takes into account the correlation between the two smoking variables by describing the EOR per pack-year in terms of delivery rate of exposure. Our analyses also included stratified groups based on major lung cancer histology subtypes. Furthermore, we tested whether the overall lung cancer risk was determined by the combined action of multiple SNPs within the same gene, despite possible null effects in single SNP associations. We analyzed multiple SNPs jointly and performed gene haplotype analysis. The information on gene expression was limited to a subgroup of 44 subjects with adenocarcinoma, but can help clarify biological mechanisms behind the measured associations of lung cancer with polymorphisms in phase I metabolic genes. We prioritized our findings based on a low p-value threshold (p-value</=0.01) and consistency across different analyses. In order to address concerns related to multiple testing and a priori knowledge considerations, we computed the False Positive Report Probability (FPRP) [55].
###end p 9
###begin title 10
Results
###end title 10
###begin title 11
Gene polymorphism and population characteristics
###end title 11
###begin p 12
###xml 67 74 67 74 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0005652-t001">Table 1</xref>
###xml 123 132 123 132 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0005652.s001">Figure S1</xref>
The 25 SNPs selected from phase I metabolic genes are presented in Table 1. The gene coverage is described in Supplemental Figure S1. All analyses were restricted to subjects with at least a 90% genotype call rate (i.e. 34 subjects were excluded). All 25 SNPs passed the test for Hardy-Weinberg equilibrium genotype proportions among the 2041 controls, with a p-value of 0.05 as the threshold.
###end p 12
###begin title 13
List of studied genes, polymorphisms, and corresponding characteristics.
###end title 13
###begin p 14
According to SNP500 database.
###end p 14
###begin p 15
Minor Allele and Minor Allele Frequency (MAF) are based on EAGLE controls.
###end p 15
###begin p 16
###xml 0 7 0 7 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0005652-t002">Table 2</xref>
###xml 710 714 710 714 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005652-Schottenfeld1">[56]</xref>
###xml 561 567 <span type="species:ncbi:9606">people</span>
Table 2 shows the frequency distributions and lung cancer association estimates for the main covariate, among the 4016 subjects included in the study. Age, sex and residential area were unrelated to case status, since frequency matching on these factors was in the design. As expected, all smoking related variables were associated with lung cancer, with increasing risks by increasing smoking exposures. Recent former smokers (up to 5 years) showed a higher risk for lung cancer compared to the current smokers. This is likely an artifact due to the fact that people typically quit smoking because of pre-clinical symptoms of lung cancer rather than a reflection of increasing risks in those who quit smoking [56]. In the analyses of genetic association we added the covariate "years since quit smoking" to the model, to adjust both for this reverse causation and for the attenuation of the risk over time.
###end p 16
###begin title 17
Characteristics of lung cancer cases and controls from the EAGLE population with genotype call rate >/=90%, and their association with lung cancer status.
###end title 17
###begin p 18
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">#</sup>
#Two-sided Wald test.
###end p 18
###begin p 19
ORs adjusted for age and area.
###end p 19
###begin p 20
ORs adjusted for sex and area.
###end p 20
###begin p 21
ORs adjusted for sex and age.
###end p 21
###begin p 22
ORs adjusted for sex, age and area.
###end p 22
###begin title 23
SNP and lung cancer risk overall and by histology
###end title 23
###begin p 24
###xml 0 7 0 7 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0005652-t003">Table 3</xref>
###xml 30 35 30 35 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">trend</sub>
###xml 197 205 195 203 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0005652.s003">Table S1</xref>
Table 3 reports results with ptrend</=0.05 for the main effect associations between each SNP and lung cancer risk overall and by histology. The complete list of results is reported in Supplemental Table S1.
###end p 24
###begin title 25
###xml 145 152 145 152 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">italics</italic>
Polymorphisms associated with risk of lung cancer overall and by histology with a significant trend (in bold) or nominally significant trend (in italics).
###end title 25
###begin p 26
ORs were adjusted for age, sex, area, cigarette per day, total pack-years, years since quit smoking.
###end p 26
###begin p 27
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">#</sup>
#Two-sided Wald test.
###end p 27
###begin p 28
###xml 68 75 68 75 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">heterog</sub>
###xml 106 112 106 112 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP1B1</italic>
###xml 200 205 200 205 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">trend</sub>
###xml 303 309 301 307 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP1B1</italic>
###xml 371 377 369 375 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP1B1</italic>
###xml 392 398 390 396 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP1B1</italic>
###xml 527 532 525 530 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">trend</sub>
###xml 580 587 578 585 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">heterog</sub>
In adenocarcinoma cases only (test for heterogeneity by histology: pheterog = 0.066), the minor allele of CYP1B1 rs10175368 was significantly protective for lung cancer (OR = 0.8, 95%CI = 0.69-0.93, ptrend = 0.003) and a similar protective effect was nominally significant (i.e. p-value</=0.05) for the CYP1B1 rs9341266 polymorphism. The cumulative number of variants in CYP1B1 rs9341266 and CYP1B1 rs10175368 also conferred a significant protection for lung cancer in adenocarcinoma cases only (OR = 0.83, 95%CI = 0.74-0.94, ptrend = 0.002; test for heterogeneity by histology: pheterog = 0.058), in concordance with the two results from the single SNP analyses.
###end p 28
###begin p 29
###xml 4 10 4 10 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2A6</italic>
###xml 162 167 162 167 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">trend</sub>
###xml 215 222 215 222 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">heterog</sub>
###xml 456 461 456 461 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">trend</sub>
The CYP2A6 rs1801272 polymorphism was significantly associated with a decreased lung cancer risk in squamous cell carcinoma cases (OR = 0.47, 95%CI = 0.27-0.81, ptrend = 0.007; test for heterogeneity by histology: pheterog = 0.045). The protective effect was nominally significant in the overall population. Interestingly, the same SNP was significantly associated with a decrease of cigarette smoking intensity in controls (OR = 0.86, 95%CI = 0.78-0.94, ptrend = 0.0007).
###end p 29
###begin title 30
Genotype-smoking interaction
###end title 30
###begin p 31
###xml 187 194 187 194 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0005652-t004">Table 4</xref>
###xml 241 249 241 249 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0005652.s004">Table S2</xref>
We repeated the analyses within subgroups defined by smoking status (never and ever smokers) in all cases and controls and, separately, in adenocarcinoma cases only and all controls (see Table 4 for the single SNP analysis, and Supplemental Table S2 for the joint SNP analysis). The other histology groups included too few never smokers to perform a meaningful analysis.
###end p 31
###begin title 32
###xml 132 139 132 139 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">italics</italic>
Associations between SNPs and lung cancer risk by never/ever smoking status, for significant (in bold) or nominally significant (in italics) smoking-genotype interactions.
###end title 32
###begin p 33
ORs were adjusted for age, sex, area.
###end p 33
###begin p 34
ORs were adjusted for age, sex, area, cigarette per day, total pack-years, years since quit smoking.
###end p 34
###begin p 35
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">#</sup>
#Two-sided Wald test.
###end p 35
###begin p 36
###xml 37 43 37 43 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP1A1</italic>
###xml 44 46 44 46 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A2</italic>
###xml 233 239 233 239 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP1A1</italic>
###xml 252 260 252 260 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">interact</sub>
###xml 347 353 347 353 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP1A2</italic>
Three SNPs in the chr15q24.1 region (CYP1A1/A2) showed a protective effect for lung cancer among never smokers but a tendency towards increased risk of lung cancer in ever smokers, with a significant genotype-smoking interaction for CYP1A1 rs2606345 (pinteract = 0.005) and a nominally significant genotype-smoking interaction for the two SNPs in CYP1A2.
###end p 36
###begin p 37
###xml 68 74 68 74 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP1A1</italic>
###xml 156 160 156 160 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005652-Lubin1">[54]</xref>
###xml 435 443 435 443 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005652-g001">Figure 1</xref>
###xml 514 523 514 523 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005652-g001">Figure 1A</xref>
###xml 528 537 528 537 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005652-g001">Figure 1B</xref>
###xml 639 645 639 645 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP1A1</italic>
###xml 681 690 681 690 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005652-g001">Figure 1A</xref>
###xml 761 767 761 767 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP1A1</italic>
###xml 819 828 819 828 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005652-g001">Figure 1B</xref>
###xml 885 891 885 891 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">versus</italic>
###xml 907 916 907 916 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005652-g001">Figure 1C</xref>
###xml 921 930 921 930 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005652-g001">Figure 1D</xref>
###xml 1041 1050 1041 1050 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005652-g001">Figure 1C</xref>
###xml 1112 1121 1112 1121 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005652-g001">Figure 1D</xref>
###xml 1208 1216 1208 1216 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005652-g001">Figure 1</xref>
###xml 1706 1714 1706 1714 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">interact</sub>
###xml 1752 1760 1752 1760 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">interact</sub>
We further explored the significant genotype-smoking interaction in CYP1A1 rs2606345 by means of the linear-exponential model for smoking excess odds ratio [54], and evaluated whether the variation in smoking risk by genotype resulted from the interaction with smoking intensity or with total pack-years and whether this interaction was present among other categories of smokers such as current or former smokers. Results are shown in Figure 1. The EOR per pack-years in current smokers compared to never smokers (Figure 1A and Figure 1B) increased for increasing number of cigarettes per day, reaching a plateau for subjects carrying the CYP1A1 rs2606345 homozygote major allele (Figure 1A), and in contrast, increasing exponentially for subjects carrying the CYP1A1 rs2606345 heterozygote or homozygote minor allele (Figure 1B). The same analysis of EOR/pack-years in former smokers versus never smokers (Figure 1C and Figure 1D) similarly showed that the EOR increase for cigarettes per day was lower in homozygote major allele carriers (Figure 1C) than for heterozygote or homozygote minor alleles carriers (Figure 1D), but here EOR/pack-years reached a plateau among both groups of subjects. Panel E in Figure 1 reports the estimated deviances and p-values for the genotype-smoking interaction among current and former smokers for the model including both interaction terms between the genotype and pack-years and between the genotype and cigarettes per day, and for intermediate models including either the interaction term between genotype and pack-years, or the interaction term between genotype and cigarettes per day. The overall genotype-smoking interaction was stronger among current smokers (pinteract = 0.009) than among former smokers (pinteract = 0.124). Among current smokers, the removal of pack-years from the model did not degrade fit relative to the full model (p = 0.209), whereas the removal of cigarettes per day did degrade fit (p = 0.022), suggesting that the genotype interaction effects resulted from cigarettes per day and not pack-years.
###end p 37
###begin title 38
###xml 46 62 46 62 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP1A1/rs2606345</italic>
Estimates of the smoking excess odds ratio by CYP1A1/rs2606345 status.
###end title 38
###begin p 39
###xml 261 267 261 267 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP1A1</italic>
###xml 348 355 348 355 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">T/G+G/G</italic>
###xml 412 415 412 415 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">T/T</italic>
###xml 420 427 420 427 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">T/G+G/G</italic>
###xml 470 473 470 473 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">T/T</italic>
###xml 478 485 478 485 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">T/G+G/G</italic>
Estimates of the linear slope parameter (EOR per pack-year) and its 95 percent confidence interval within categories of smoking intensity (square symbol) and fitted linear-exponential odds ratio for continuous pack-years and cigarettes per day (solid line) for CYP1A1 rs2606345. The Figure shows results for T/T genotype in panels A and C, and for T/G+G/G genotypes in panels B and D, among current smokers (700 T/T+997 T/G+G/G) (panels A and B) and former smokers (640 T/T+855 T/G+G/G) (panels C and D). The table in panel E reports the estimated deviances and p-values for the genotype-smoking interaction among current and former smokers for the model including both interaction terms between the genotype and pack-years and between the genotype and cigarette per day, and for intermediate models including either the interaction term between genotype and pack-years, or the interaction term between genotype and cigarette per day. The significant increase in deviance in current smokers is mainly due to the interaction term of the genotype with cigarettes per day and not with pack-years; the removal of pack-years from the model did not degrade fit relative to the full model (p = 0.209), whereas the removal of cigarettes per day did degrade fit (p = 0.022).
###end p 39
###begin p 40
###xml 75 83 75 83 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0005652.s004">Table S2</xref>
###xml 139 145 139 145 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP1A1</italic>
###xml 150 156 150 156 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP1A2</italic>
###xml 283 288 283 288 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">trend</sub>
###xml 382 387 382 387 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">trend</sub>
###xml 456 464 456 464 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">interact</sub>
In the joint analysis of multiple SNPs stratified by smoking (Supplemental Table S2), the cumulative number of variants of all 8 SNPs from CYP1A1 and CYP1A2 in the chr15q24.1 region conferred a significant overall risk for lung cancer in ever smokers (OR = 1.03, 95%CI = 1.00-1.07, ptrend = 0.040) and a borderline protective effect in never smokers (OR = 0.91, 95%CI = 0.84-0.99, ptrend = 0.055). The smoking-genotype interaction was highly significant (pinteract = 0.006).
###end p 40
###begin p 41
###xml 33 39 33 39 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2A6</italic>
In addition, the minor allele of CYP2A6 rs1801272 showed a significant protective effect in ever smokers, increased risk in never smokers, and a nominally significant genotype-smoking interaction.
###end p 41
###begin title 42
Linkage disequilibrium and haplotype analysis
###end title 42
###begin p 43
###xml 196 203 196 203 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0005652.s007">Text S1</xref>
###xml 208 217 208 217 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0005652.s002">Figure S2</xref>
For genes represented by two or more SNPs, we computed linkage disequilibrium (LD) among controls and haplotype association with lung cancer. The complete results are reported in the Supplemental Text S1 and Figure S2.
###end p 43
###begin p 44
###xml 56 61 56 61 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EPHX1</italic>
###xml 86 87 86 87 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 116 117 114 115 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 129 134 127 132 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EPHX1</italic>
###xml 149 154 147 152 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EPHX1</italic>
###xml 271 279 269 277 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">TGGCACTC</named-content>
###xml 371 379 369 377 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">CGGCGCCT</named-content>
###xml 552 560 550 558 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">TGGCACTC</named-content>
###xml 583 591 581 589 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">CGGCGCCT</named-content>
###xml 827 835 825 833 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0005652.s005">Table S3</xref>
Interestingly, the haplotype analysis for the 8 SNPs in EPHX1 (which were in low LD: r2</=0.1 for most SNPs pairs, r2 = 0.43 for EPHX1 rs2234922 and EPHX1 rs1051741) revealed two haplotypes significantly associated with lung cancer in the overall population: carriers of TGGCACTC haplotype had higher risk than non-carriers (freq = 0.01, p-value = 0.010) and carriers of CGGCGCCT haplotype had a lower risk than non-carriers (freq = 0.01, p-value = 0.015). In addition, we found similar results in the analysis restricted to adenocarcinoma cases only: TGGCACTC (p-value = 0.008) and CGGCGCCT (p-value = 0.023). Since the 8 SNPs were in low LD, we also performed a three marker moving window haplotype analysis and found no significant associations between lung cancer and haplotype combinations of three SNPs (see Supplemental Table S3). However, we identified a borderline significant protective association (freq = 0.03, p-value = 0.059) with a three-locus haplotype with a C, G, and T in locus 1, 2 and 8, respectively, which was also contained in the 8 SNP haplotype.
###end p 44
###begin p 45
###xml 104 110 104 110 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP1A1</italic>
###xml 138 144 138 144 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP1A2</italic>
###xml 163 172 163 172 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0005652.s002">Figure S2</xref>
###xml 290 295 290 295 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">GTAAA</named-content>
###xml 328 333 328 333 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">CGGGG</named-content>
For the 8 SNPs in the chr15q24.1 region, we found two regions of LD, one of modest strength surrounding CYP1A1, and a second region 3' of CYP1A2 (see Supplemental Figure S2), concordant with the results from HapMap. Haplotype analyses were computed separately for these two LD regions; the GTAAA haplotype (freq = 0.07) and the CGGGG haplotype (freq = 0.03) were nominally significantly associated with lung cancer risk in never and ever smokers respectively.
###end p 45
###begin title 46
Association between genotype and gene expression
###end title 46
###begin p 47
###xml 112 120 112 120 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0005652.s006">Table S4</xref>
###xml 252 258 252 258 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP1A1</italic>
###xml 446 452 438 444 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP1B1</italic>
###xml 522 528 514 520 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP1B1</italic>
###xml 648 653 636 641 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EPHX1</italic>
The complete results for the correlation between genotype and gene expression data are reported in Supplemental Table S4. We found that the 8 polymorphisms in the 15q24 chromosomal region had a significant down-regulating effect on mRNA expression for CYP1A1 gene among the 14 never smokers (delta = -1.51, p-value = 0.007) and showed a trend for up-regulation among the 15 current smokers (delta = 4.95, p-value = 0.078). The 7 polymorphisms in CYP1B1 were significantly associated with an increase of mRNA expression in CYP1B1 among the 15 current smokers (delta = 8.99, p-value = 0.004), and not among the 44 subjects overall. For the 8 SNPs in EPHX1 gene, we observed an overall trend for decreasing expression (delta = -1.20, p-value = 0.096), which was nominally significant among the 15 former smokers (delta = -2.56, p-value = 0.049).
###end p 47
###begin title 48
Multiple testing
###end title 48
###begin p 49
###xml 19 26 19 26 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0005652-t005">Table 5</xref>
FPRP calculations (Table 5) were performed for nominally significant or significant single SNP analysis results. The table shows that all prior probabilities of >/=0.10 had low FPRP values (<0.5).
###end p 49
###begin title 50
False positive report probability.
###end title 50
###begin p 51
###xml 103 110 103 110 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0005652-t003">Table 3</xref>
###xml 152 159 152 159 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0005652-t004">Table 4</xref>
FPRP values for the nominally significant (p-value<0.05) results from test of main single SNP effects (Table 3) and of SNP-smoking interaction effects (Table 4). FPRP is computed according to the formula alpha(1-pi)/[alpha(1-pi)+(1-beta)pi], where alpha and (1-beta) are the P-value and Power values reported in the table, and pi represents the Prior Probability ranging from 0.001 to 0.5. FPRP values less than 0.2 are in italic, FPRP values between 0.2 and 0.5 are bold, and FPRP values larger than 0.5 are the rest.
###end p 51
###begin p 52
Test for main genetic effect among all subjects.
###end p 52
###begin p 53
Test for main genetic effect among controls and adenocarcinoma cases.
###end p 53
###begin p 54
Test for main genetic effect among controls and squamous carcinoma cases.
###end p 54
###begin p 55
Test for gene-smoking interaction among all subjects.
###end p 55
###begin p 56
Test for gene-smoking interaction among controls and adenocarcinoma cases.
###end p 56
###begin p 57
OR indicates the measured odds ratio for the main genetic effect for tests (a), (b), and (c), and the measured odds-ratio ratio for the gene-smoking interaction effect for tests (d) and (e).
###end p 57
###begin p 58
The statistical power to detect the measured OR given a type I error rate of 0.05 was computed by means of the QUANTO software ().
###end p 58
###begin title 59
Discussion
###end title 59
###begin p 60
###xml 87 92 87 92 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EPHX1</italic>
###xml 94 100 94 100 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP1A1</italic>
###xml 102 108 102 108 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP1B1</italic>
###xml 113 119 113 119 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2A6</italic>
In this large population-based case-control study of lung cancer we have observed that EPHX1, CYP1A1, CYP1B1 and CYP2A6 genes may play a role in lung cancer susceptibility.
###end p 60
###begin p 61
###xml 18 23 18 23 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EPHX1</italic>
###xml 164 172 164 172 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">TGGCACTC</named-content>
###xml 194 202 194 202 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">CGGCGCCT</named-content>
###xml 1289 1294 1289 1294 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EPHX1</italic>
###xml 1344 1349 1344 1349 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EPHX1</italic>
###xml 1406 1410 1406 1410 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005652-Graziano1">[39]</xref>
###xml 1431 1435 1431 1435 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005652-ToFigueras1">[57]</xref>
###xml 1642 1647 1642 1647 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EPHX1</italic>
###xml 1677 1682 1677 1682 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EPHX1</italic>
###xml 1698 1703 1698 1703 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EPHX1</italic>
###xml 1800 1807 1800 1807 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0005652-t003">Table 3</xref>
###xml 1860 1865 1860 1865 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EPHX1</italic>
###xml 481 487 <span type="species:ncbi:9606">people</span>
###xml 1959 1967 <span type="species:ncbi:9606">patients</span>
Two haplotypes in EPHX1 compared to all other haplotypes were significantly associated with lung cancer in the overall population and in adenocarcinoma cases only: TGGCACTC as a risk factor and CGGCGCCT as a protective factor. In addition, we identified a borderline significant protective association with a three-locus haplotype which was also contained in the 8SNP haplotype and was present in approximately 3% of the population. These findings suggest that more than a hundred people in our study carried a three-variant haplotype resulting in a decreased lung cancer risk. The protective effect was even stronger for the smaller number of subjects (1%) who carried a combination of these three SNPs and the remaining 5 SNPs in the 8-locus haplotype. Since the significant associations with lung cancer were based on relatively rare haplotypes, replication will be needed in order to validate this finding. None of the 8 SNPs was significantly associated with lung cancer in the overall population when analyzed separately. This result, if confirmed, demonstrates that the effect of multiple SNPs on lung cancer may be important even if most individual SNPs do not show significant association. This may explain why previously published results, which are based on a limited number of EPHX1 polymorphisms, were inconsistent. In particular, EPHX1 rs2234922 has been previously associated both with risk [39] and with protection [57] for lung cancer. This SNP was not associated with lung cancer in our data. Nevertheless it was one of the three SNPs that differentiate the two significant haplotypes reported here. The other two SNPs were EPHX1 rs1051741, in medium LD with EPHX1 rs2234922, and EPHX1 rs2292568, nominally significantly associated with risk of lung adenocarcinoma in our data (see Table 3). We did not find a significant association between EPHX1 polymorphisms and gene expression. Measurements of epoxide hydrolase activity in lung cancer patients carrying these haplotypes will be needed in order to understand the biological mechanism that underlies this finding.
###end p 61
###begin p 62
###xml 62 68 62 68 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP1A1</italic>
###xml 73 79 73 79 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP1A2</italic>
###xml 253 259 253 259 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP1A1</italic>
###xml 330 336 330 336 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP1A2</italic>
###xml 455 461 455 461 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP1A1</italic>
###xml 466 472 466 472 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP1A2</italic>
###xml 670 676 670 676 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al.</italic>
###xml 676 680 676 680 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005652-Wang2">[58]</xref>
###xml 740 746 740 746 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP1A1</italic>
###xml 1300 1306 1300 1306 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP1A1</italic>
###xml 1415 1421 1415 1421 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP1A1</italic>
###xml 1671 1680 1671 1680 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP1A1/A2</italic>
###xml 855 860 <span type="species:ncbi:9606">women</span>
###xml 924 929 <span type="species:ncbi:9606">women</span>
A group of SNPs from two LD regions in the chr15q24.1 region (CYP1A1 and CYP1A2) showed a protective effect on lung cancer risk among never smokers and a suggestive risk of lung cancer in ever smokers with a significant genotype-smoking interaction for CYP1A1 rs2606345 and a nominally significant interaction for the two SNPs in CYP1A2. This result was confirmed by the multiple SNP analysis stratified by smoking. The cumulative number of variants from CYP1A1 and CYP1A2 was in fact associated with a significant risk for lung cancer in ever smokers and a protective effect in never smokers, with a highly significant smoking-genotype interaction. Interestingly, Wang et al.[58] recently reported an analogous inverse association between CYP1A1 rs2606345 and levels of DNA adducts: the variant allele was associated with high level of DNA adducts among women with high PAH exposure and with low level of DNA adducts among women with low PAH exposure. Further, using the linear-exponential model for smoking EOR we found that the difference in smoking effects between the wild type and the variant resulted from the effects of cigarettes per day and not pack-years. This finding suggests that a dose-response mechanism and a saturation effect might underlie the smoking-mediated association between CYP1A1 and lung cancer risk. The gene expression analysis supported this finding. In fact, the lower expression of CYP1A1 among never smokers and higher expression among current smokers in association with the SNPs at chr15q24.1 was consistent with the observed protective effect for lung cancer among never smokers and risk among smokers in association with variants in CYP1A1/A2.
###end p 62
###begin p 63
###xml 46 52 46 52 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP1B1</italic>
###xml 224 230 224 230 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP1B1</italic>
###xml 243 244 243 244 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 361 367 361 367 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP1B1</italic>
###xml 504 514 504 514 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0005652.s001">Figure S1B</xref>
###xml 617 623 617 623 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP1B1</italic>
###xml 748 752 748 752 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005652-Cote1">[27]</xref>
###xml 753 757 753 757 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005652-Zienolddiny1">[30]</xref>
###xml 759 763 759 763 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005652-Sorensen1">[59]</xref>
###xml 765 769 765 769 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005652-Liang1">[60]</xref>
###xml 925 929 925 929 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005652-Shah2">[28]</xref>
###xml 931 935 931 935 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005652-Zienolddiny1">[30]</xref>
###xml 1296 1302 1296 1302 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP1B1</italic>
###xml 1354 1358 1354 1358 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005652-Aklillu1">[26]</xref>
###xml 1401 1407 1401 1407 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP1B1</italic>
###xml 1568 1574 1568 1574 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP1B1</italic>
###xml 1611 1617 1611 1617 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP1B1</italic>
###xml 1722 1728 1722 1728 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP1B1</italic>
###xml 1818 1824 1818 1824 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP1B1</italic>
###xml 1868 1874 1868 1874 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP1B1</italic>
###xml 1994 2000 1994 2000 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP1B1</italic>
###xml 2044 2048 2044 2048 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005652-Landi2">[61]</xref>
###xml 2088 2094 2088 2094 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP1B1</italic>
###xml 1943 1951 <span type="species:ncbi:9606">patients</span>
Our data also showed that the minor allele of CYP1B1 rs10175368 was significantly protective for adenocarcinoma of the lung (OR = 0.80, 95%CI = 0.69-0.93) and a similar protective effect was observed for the minor allele of CYP1B1 rs9341266 (r2 = 0.30), as well as for the cumulative sum of the two minor alleles. In addition, according to the HapMap database, CYP1B1 rs10175368 is in LD with 4 other SNPs in the same chromosomal region (rs2551188, rs4646430, rs4646429, and rs10175338, see Supplemental Figure S1B). These 4 SNPs are likely to be characterized by the same protective association. Previous results on CYP1B1 polymorphisms and lung cancer have been limited to the four non-synonymous SNPs rs10012, rs1056827, rs1056836 and rs1800440 [27]-[30], [59], [60]. None of the reported positive findings have been consistently replicated, except for rs10012, associated with lung cancer risk in two independent studies [28], [30]. Our data on rs1800440 did not show any significant association with lung cancer. The three other non-synonymous SNPs were not evaluated in the current study. However, our SNPs were selected with an attempt to cover other regions of the gene. According to our data, variants other than those in the coding region could alter lung cancer risk. Polymorphisms in CYP1B1 have been associated with decreased PAH metabolism [26]. The significant protective effect of the CYP1B1 rs10175368 variant allele could be due to a lower level of smoking carcinogens in subjects carrying the variant allele. We did not find a significant effect on CYP1B1 gene expression for the two SNPs in CYP1B1 associated with a protection for adenocarcinoma. However, when we considered all seven polymorphisms in CYP1B1 together and studied their effect on gene expression, we found a significant increase in CYP1B1 gene expression among current smokers. The CYP1B1 gene is known to be highly expressed in lung tissues of lung cancer patients. Our result supports previous findings of CYP1B1 gene over-expression among current smokers [61] and suggests a possible involvement of CYP1B1 polymorphisms as a mechanism for differential expression.
###end p 63
###begin p 64
###xml 4 10 4 10 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2A6</italic>
###xml 78 81 78 81 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Leu</italic>
###xml 85 88 85 88 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">His</italic>
###xml 387 391 387 391 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005652-Pianezza1">[46]</xref>
###xml 499 500 499 500 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</italic>
###xml 511 517 511 517 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2A6</italic>
###xml 737 743 737 743 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2A6</italic>
###xml 1061 1067 1061 1067 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2A6</italic>
###xml 1224 1228 1224 1228 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005652-Pianezza1">[46]</xref>
###xml 1303 1307 1303 1307 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005652-London1">[43]</xref>
###xml 1308 1312 1308 1312 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005652-Pianezza1">[46]</xref>
###xml 361 368 <span type="species:ncbi:4097">tobacco</span>
###xml 1376 1383 <span type="species:ncbi:4097">tobacco</span>
The CYP2A6 rs1801272 polymorphism, which results in an amino acid change from Leu to His, was significantly associated with a decreased risk for squamous cell carcinoma, a strictly smoking-related malignancy. Interestingly, the same SNP was associated with a decrease in cigarettes per day in controls, confirming a previously hypothesized role of this gene in tobacco smoking addiction [46]. Our report provides the first confirmation of this finding in a population-based sample. In addition, the A allele of CYP2A6 rs1801272 showed a significant protective effect in ever smokers but no effect in never smokers, with a nominally significant genotype-smoking interaction due to the effect of cigarettes per day and not pack-years. The CYP2A6 gene is characterized by multiple polymorphisms and genomic repetitive elements in the regulatory regions, which make a complete coverage of the gene extremely challenging. Moreover, most variants are very rare in the general population and would not be identifiable even in a large sample size as ours. We genotyped CYP2A6 rs1801272 (also known as CYP2A6*2) because this SNP is relatively common (4% in our population), has been well characterized in previous functional studies [46], and showed controversial associations with cancer and smoking dependence [43]-[46]. Our findings of an association with both lung cancer risk and tobacco addiction warrant further investigation based on a more complete coverage of this gene.
###end p 64
###begin p 65
###xml 169 174 169 174 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EPHX1</italic>
###xml 186 192 186 192 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP1B1</italic>
###xml 208 211 208 211 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MPO</italic>
###xml 307 314 307 314 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0005652-t005">Table 5</xref>
The size of our population provides unusual power for confirming previously reported associations. Our data do not support proposed associations between lung cancer and EPHX1 rs2234922, CYP1B1 rs1800440, and MPO rs2333227. The confidence in our significant results was supported by the low FPRP values (see Table 5) observed for prior probabilities of 0.10 or more given the strong prior probabilities of the selected phase I genes being involved in lung cancer risk.
###end p 65
###begin p 66
###xml 463 472 463 472 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0005652.s001">Figure S1</xref>
At the time that this project was initiated, there was less genotype data available with which to select SNPs to cover haplotype blocks. Nevertheless, based on the existing SNP500Cancer and comparative assessment of HapMap data, we selected SNPs that represented tagSNPs in the Caucasian population. Although the coverage is inevitably incomplete, we substantially improved the coverage of the selected genes in comparison with previous studies (see Supplemental Figure S1).
###end p 66
###begin p 67
Strengths of our study include a population-based design, large sample size with adequate power to detect main gene effect and gene-smoking interaction effect, integrative analysis with gene expression data, and a systematic approach in evaluating the joint effects of multiple SNPs.
###end p 67
###begin p 68
###xml 127 132 127 132 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EPHX1</italic>
###xml 478 484 478 484 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP1A1</italic>
###xml 837 844 <span type="species:ncbi:4097">tobacco</span>
Our results are particularly timely in relation to recent GWAS. For example, the significant association between haplotypes in EPHX1 and lung cancer risk emphasizes that the effect of multiple SNPs may be important despite null associations in single SNP analyses, and should be taken into consideration in GWAS. Similarly, although further study is necessary to confirm the qualitative interaction between smoking and genotype in relation to lung cancer susceptibility for the CYP1A1 rs2606345, this finding is particularly interesting, considering that this SNP is not included in the HapMap database or in the common platforms used for GWAS, although it is in relatively strong LD with other SNPs in these platforms. This highlights the necessity of fine mapping after GWAS to further elucidate associations with lung cancer risk and tobacco smoking addiction. In conclusion, this study emphasizes the importance of ample coverage of genes in the analysis of genetic susceptibility of cancer, integration with corresponding gene function in the target tissue, and rigorous study design and analytical approach.
###end p 68
###begin title 69
Materials and Methods
###end title 69
###begin title 70
Study population and data collection
###end title 70
###begin p 71
###xml 70 73 70 73 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005652-Landi1">[6]</xref>
###xml 1296 1303 1296 1303 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0005652-t002">Table 2</xref>
###xml 1103 1115 <span type="species:ncbi:9606">participants</span>
A detailed description of the EAGLE study has been recently published [6]. Briefly, the study includes 2101 incident lung cancer cases and 2120 population controls enrolled in the period April 2002-June 2005 in 216 municipalities from the Lombardy region (Italy). Cases were subjects with primary cancer of trachea, bronchus and lung, first diagnosed between April 22, 2002 and February 28, 2005, and admitted to 13 hospitals of the study area. Controls were randomly sampled from population databases, frequency matched to cases by area of residence (5 classes), gender, and age (5-year categories), and contacted through the family physician. All enrolled subjects were Caucasian. Subjects were 35-79 years of age at diagnosis (cases) or at sampling/enrollment for interview (controls). The study participation rates were 86.6% among cases and 72.4% among controls. After signing an Institutional Review Board-approved informed consent form, subjects underwent a computer-assisted personal interview (CAPI) and filled-in a self-administered questionnaire. Biospecimens (blood or buccal rinse from all participants and pathological samples from cases) were collected. Epidemiological information on the 4016 EAGLE subjects with available genotype data and analyzed in this study is described in Table 2.
###end p 71
###begin title 72
SNP selection and genotyping
###end title 72
###begin p 73
###xml 383 390 383 390 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0005652-t001">Table 1</xref>
###xml 414 419 414 419 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EPHX1</italic>
###xml 421 427 421 427 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP1B1</italic>
###xml 433 442 433 442 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP1A1/A2</italic>
###xml 524 533 524 533 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0005652.s001">Figure S1</xref>
###xml 539 545 539 545 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2A6</italic>
###xml 550 553 550 553 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MPO</italic>
###xml 659 663 659 663 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005652-London1">[43]</xref>
###xml 664 668 664 668 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005652-Kamataki1">[45]</xref>
###xml 670 674 670 674 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005652-Feyler1">[52]</xref>
###xml 676 680 676 680 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005652-Xu1">[53]</xref>
At the start of the study, SNP assays were selected from those available at the Core Genotyping Facility (CGF) of the Division of Cancer Epidemiology and Genetics (National Cancer Institute), using our own assessment of linkage disequilibrium between the SNPs from HapMap and previous evidence from the literature. The 25 SNPs selected from phase I metabolism genes are presented in Table 1. The gene coverage for EPHX1, CYP1B1, and CYP1A1/A2 based on the present version of the HapMap database is described in Supplemental Figure S1. For CYP2A6 and MPO genes, we selected only two SNPs whose association with lung cancer has been debated in previous studies [43]-[45], [52], [53]. Genotyping of the 25 SNPs was done at the CGF with the TaqMan(R) assay, described at the National Cancer Institute SNP500Cancer website (). Genotyping was performed on 4050 EAGLE subjects (those with sufficient DNA samples). Duplicate quality-control samples (2% of the total) showed 100% agreement for all 25 assays.
###end p 73
###begin title 74
Gene expression data
###end title 74
###begin p 75
###xml 241 245 241 245 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005652-Landi2">[61]</xref>
In addition to genotype information, we analyzed mRNA gene expression data from an Affymetrix HG-U133A microarray using fresh tissue samples from a subgroup of adenocarcinoma cases. The original microarray study has been described elsewhere [61]. Here, we analyzed the gene expression data from non-tumor samples of 44 subjects in relation to genotype data from the same subjects, as described in the Statistical analysis section.
###end p 75
###begin title 76
Statistical analysis
###end title 76
###begin p 77
Most analyses were implemented and performed using the R-project (version 2.8) statistical package (). The EOR smoking model was implemented in Epicure ().
###end p 77
###begin title 78
A. Main effect of genotype
###end title 78
###begin p 79
The main effect of the variant genotypes on the risk of lung cancer was estimated by odds ratios and their 95% confidence intervals using unconditional logistic regression analysis. Homozygosity for the more frequent allele among controls was defined as the reference group. We tested for significance using two-sided Wald tests. The trend test for the effect of SNP was conducted by including the SNP variable as continuous in logit scale in the model, and the categorical analysis was performed by treating the SNP variable as three levels categorical variable. Age, sex, geographical location, cumulative smoking dose (pack-years), smoking intensity (cigarettes per day), and quitting smoking (years since quit) were selected as covariates. We performed stratified analyses by smoking status (never/ever) of cases and controls and polytomous logistic regression by the major histology types (adenocarcinoma, squamous cell carcinoma, and small cell carcinoma) of cases. In the analysis by histology, we defined the standard Wald chi-square test statistic using the coefficient estimates derived from a polytomous logistic regression (where the response variable was coded on four levels: controls, adenocarcinoma cases, squamous cells carcinoma cases, and small cells carcinoma cases) and the covariance matrix of the coefficients.
###end p 79
###begin title 80
B. Genotype-smoking interaction
###end title 80
###begin p 81
We evaluated genotype-smoking interactions using a likelihood ratio test to compare the following two models:
###end p 81
###begin p 82
###xml 17 18 13 14 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">0</sub>
###xml 48 53 38 39 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#947;</underline>
###xml 54 64 40 50 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">covariates</underline>
###xml 0 64 0 50 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Logit(LC)&#8202;=&#8202;&#945;<sub>0</sub>+&#946;&#215;SNP+&#950;&#215;smoking status+<underline>&#947;</underline>&#215;<underline>covariates</underline></italic>
###xml 64 65 50 51 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">,</underline>
Logit(LC) = alpha0+betaxSNP+zetaxsmoking status+gammaxcovariates,
###end p 82
###begin p 83
###xml 17 18 13 14 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">0</sub>
###xml 73 78 59 60 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#947;</underline>
###xml 79 89 61 71 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">covariates</underline>
###xml 0 89 0 71 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Logit(LC)&#8202;=&#8202;&#945;<sub>0</sub>+&#946;&#215;SNP+&#950;&#215;smoking status+&#952;&#215;SNP&#215;smoking status+<underline>&#947;</underline>&#215;<underline>covariates</underline></italic>
Logit(LC) = alpha0+betaxSNP+zetaxsmoking status+thetaxSNPxsmoking status+gammaxcovariates.
###end p 83
###begin p 84
###xml 171 175 171 175 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005652-Lubin1">[54]</xref>
###xml 421 422 421 422 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">d</italic>
###xml 459 460 459 460 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 463 486 463 483 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OR(d,n)&#8202;=&#8202;1+&#946;&#215;d&#215;g(n)</italic>
###xml 494 498 491 492 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#946;</italic>
###xml 513 517 507 511 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">g(n)</italic>
###xml 552 556 546 550 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">g(.)</italic>
###xml 761 765 755 759 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">g(.)</italic>
###xml 787 788 779 780 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 798 799 788 789 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 805 806 795 796 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 773 807 767 797 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">g(n)&#8202;=&#8202;exp{&#981;<sub>1</sub>&#215;ln(n)+&#981;<sub>2</sub>&#215;ln(n)<sup>2</sup>}</italic>
###xml 824 833 814 820 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#946;&#215;g(n)</italic>
###xml 1075 1076 1062 1063 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">s</italic>
###xml 1084 1085 1071 1072 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">s</italic>
###xml 1189 1190 1169 1170 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">s</sub>
###xml 1194 1195 1174 1175 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">s</sub>
###xml 1158 1199 1145 1179 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OR(s,d,n)&#8202;=&#8202;exp(&#945;s)&#215;[1+&#946;<sub>s</sub>&#215;d&#215;g<sub>s</sub>(n)]</italic>
###xml 1593 1594 1570 1571 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 1601 1602 1575 1576 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">0</sub>
###xml 1589 1602 1569 1576 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#946;<sub>1</sub>&#8202;=&#8202;&#946;<sub>0</sub></italic>
###xml 1639 1646 1611 1618 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">s&#8202;=&#8202;1,1</sub>
###xml 1652 1659 1622 1629 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">s&#8202;=&#8202;0,1</sub>
###xml 1636 1659 1610 1629 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#981;<sub>s&#8202;=&#8202;1,1</sub>&#8202;=&#8202;&#981;<sub>s&#8202;=&#8202;0,1</sub></italic>
###xml 1667 1674 1635 1642 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">s&#8202;=&#8202;1,2</sub>
###xml 1680 1687 1646 1653 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">s&#8202;=&#8202;0,2</sub>
###xml 1664 1687 1634 1653 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#981;<sub>s&#8202;=&#8202;1,2</sub>&#8202;=&#8202;&#981;<sub>s&#8202;=&#8202;0,2</sub></italic>
For polymorphisms showing the presence of a genotype-smoking interaction in the association with lung cancer, we fitted a model for the excess odds ratio of smoking (EOR) [54] in order to separate the contribution of total exposure and intensity in the interaction with the polymorphism. Specifically, we fitted the following 3-parameter linear-exponential model which described the OR in terms of continuous pack-years (d) and continuous cigarettes per day (n): OR(d,n) = 1+betaxdxg(n), where beta is the EOR at g(n) = 1, i.e., the EOR/pack-year, and g(.) is a function that describes the influence of changing cigarettes per day on the strength of the lung cancer and pack-years association. Based on an empirical evaluation, we used a two parameter form for g(.), where g(n) = exp{phi1xln(n)+phi2xln(n)2}. The component, betaxg(n), describes the EOR per pack-year and its variation with cigarettes per day and thus the influence of the delivery rate, i.e., increasing cigarettes per day and decreasing duration of exposure. We expanded this model to incorporate genotype (s, where s = 1 and 0 denote the variant and wild type forms, respectively), using: OR(s,d,n) = exp(alphas)x[1+betasxdxgs(n)], where the subscripts denote separate parameters for each genotype. We fitted the model to data on never and current smokers (including subjects who quit smoking less than two years before the study) and on never and former smokers (subjects who quit smoking more than two years before the study), and used likelihood ratio tests to compare homogeneity of the effects of pack-years, i.e., beta1 = beta0, and/or smoking intensity, i.e., phis = 1,1 = phis = 0,1 and phis = 1,2 = phis = 0,2.
###end p 84
###begin title 85
C. Joint SNPs
###end title 85
###begin p 86
We analyzed multiple SNPs jointly to test whether the overall lung cancer risk was determined by the combined action of multiple SNPs within the same gene and/or of multiple genes within the same pathway, even if each SNP may have had only a modest effect size individually.
###end p 86
###begin title 87
c1
###end title 87
###begin p 88
###xml 68 78 68 78 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cumulative</italic>
###xml 121 126 121 126 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">k&#8202;=&#8202;1</italic>
###xml 128 137 128 129 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8230;</italic>
###xml 139 140 131 132 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 278 279 270 271 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 326 327 318 319 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">k</sub>
###xml 323 327 315 319 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SNP<sub>k</sub></italic>
###xml 374 375 366 367 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">k</sub>
###xml 371 375 363 367 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SNP<sub>k</sub></italic>
###xml 416 417 408 409 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">k</sub>
###xml 413 417 405 409 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SNP<sub>k</sub></italic>
###xml 455 459 447 448 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#946;</italic>
###xml 533 534 518 519 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">k</sub>
###xml 534 535 519 520 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</sup>
###xml 540 541 525 526 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">k</sub>
###xml 528 542 517 527 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#931;<sub>k</sub><sup>n</sup> (SNP<sub>k</sub>)</italic>
###xml 628 629 613 614 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 648 662 633 644 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OR&#8202;=&#8202;exp(&#946;)</italic>
Under the assumption that the effect on lung cancer of each SNP was cumulative, we implemented the following model:where k = 1, em leader, n represents a collection of SNPs belonging to the same gene or a collection of SNPs belonging to genes in the same pathway (e.g. phase I, n = 25 i.e. all SNPs were grouped together). SNPk = 0 for the homozygote most common allele, SNPk = 1 for the heterozygote allele, and SNPk = 2 for the homozygote minor allele. beta is the regression coefficient for the cumulative number of variants Sigmakn (SNPk). We estimated the overall risk of lung cancer associated with each selected group of n SNPs by computing OR = exp(beta) in the overall population, in never smokers, and in ever smokers separately. We estimated smoking-genotype interaction using the likelihood ratio test. Note that in this model we do not assume nor infer a risk direction for each minor allele. This approach will be powerful if minor alleles for all SNPs have effects in the same direction, but there may be loss of power if minor alleles for some SNPs affect lung cancer risk in opposite directions and their contribution to the overall risk cancels with each other.
###end p 88
###begin title 89
c2
###end title 89
###begin p 90
For all genes represented in our data by two or more SNPs, we computed paired linkage disequilibrium (LD) using the Haploview software and carried out haplotype analysis using the haplo.stats R-package.
###end p 90
###begin title 91
D. Gene Expression
###end title 91
###begin p 92
###xml 68 69 68 69 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">k</sub>
###xml 69 70 69 70 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">G</sup>
###xml 65 70 65 70 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SNP<sub>k</sub><sup>G</sup></italic>
###xml 89 90 89 90 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">G</italic>
###xml 131 132 131 132 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">G</italic>
###xml 250 251 250 251 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">k</sub>
###xml 251 252 251 252 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">G</sup>
###xml 247 252 247 252 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SNP<sub>k</sub><sup>G</sup></italic>
###xml 310 311 307 308 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">k</sub>
###xml 306 311 306 308 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#946;<sub>k</sub></italic>
###xml 320 321 317 318 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 354 355 351 352 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 364 365 361 362 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">G</italic>
###xml 391 392 385 386 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">k</sub>
###xml 387 392 384 386 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#946;<sub>k</sub></italic>
###xml 485 486 479 480 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">k</sub>
###xml 486 487 480 481 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">G</sup>
###xml 482 487 476 481 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SNP<sub>k</sub><sup>G</sup></italic>
###xml 524 525 518 519 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">G</italic>
###xml 530 531 524 525 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">G</sub>
###xml 527 531 521 525 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Exp<sub>G</sub></italic>
###xml 605 612 599 602 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#948;&gt;0</italic>
###xml 639 646 629 632 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#948;&lt;0</italic>
###xml 693 694 679 680 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">G</italic>
###xml 746 747 732 733 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">k</sub>
###xml 747 748 733 734 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">G</sup>
###xml 743 748 729 734 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SNP<sub>k</sub><sup>G</sup></italic>
###xml 1106 1112 <span type="species:ncbi:9606">people</span>
We evaluated to the extent possible, the effect of polymorphisms SNPkG from a given gene G on the gene expression of the same gene G, and specifically the effect related to lung cancer. We first estimated the overall effect of each group of SNPs (SNPkG) on lung cancer according to the additive modelwhere betak are the n regression coefficients for the n SNPs in G. Second, we used the betak estimated from equation (2) to compute the overall effect of each group of polymorphisms SNPkG on the change of gene expression of G (ExpG) by solving the following logistic regression:According to equation (3), delta>0 indicates an increase and delta<0 a decrease in the gene expression of the gene G, due to the overall effect of the polymorphisms SNPkG on lung cancer. Basically, we used the SNPs regression score for lung cancer and verified whether it was positively or negatively associated with gene expression in non tumor tissue samples from a subgroup of cases. Note that since we lack gene expression data from healthy controls because no fresh frozen lung tissue samples can be collected from healthy people, we cannot measure directly the association between gene expression and lung cancer risk. Combining equation (2) and (3) instead, we are able to obtain such information. The described gene expression analysis was performed overall and, separately, among never smokers, former smokers, and current smokers.
###end p 92
###begin title 93
###xml 24 32 24 32 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">a priori</italic>
E. Multiple testing and a priori knowledge considerations
###end title 93
###begin p 94
###xml 956 964 956 964 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">a priori</italic>
###xml 1205 1213 1205 1213 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">a priori</italic>
###xml 1297 1301 1297 1301 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005652-Wacholder1">[55]</xref>
We considered significant those results with a p-value less than (or equal to) 0.01. This choice was a compromise between a more stringent Bonferroni-corrected p-value and the loss in power from getting the threshold for significance too low. In addition, we referred to results with p-value between 0.01 and 0.05 as nominally significant, and considered them as notable when consistent across different analyses. Given the number of tested hypotheses in the single SNP analyses (25 tests corresponding to the 25 SNPs for the single SNP analysis and 5 tests when SNPs were grouped by genes) we took multiple testing into account. Our approach to multiple testing was informed by the selection strategy for the Phase I genes selected. Of note, each of the genes included has substantial mechanistic and at least some population data which support an association with lung cancer, as we have described in the introduction. We recognize that quantifying this a priori knowledge for each SNP is challenging, because of the heterogeneity of results in the literature and because most results actually refer to genes and not to our specific SNPs. In order to incorporate the effect of both multiple testing and a priori knowledge considerations, we computed the False Positive Report Probability (FPRP) [55] to characterize the noteworthiness for all the significant and nominally significant results from single SNP analyses for a range of prior probabilities. The statistical power to detect the measured OR given a type I error rate of 0.05 was computed by means of the QUANTO software ().
###end p 94
###begin title 95
Supporting Information
###end title 95
###begin p 96
Genes coverage for EPHX1, CYP1B1 and CYP1A1/A2
###end p 96
###begin p 97
(0.68 MB DOC)
###end p 97
###begin p 98
Click here for additional data file.
###end p 98
###begin p 99
Results for linkage disequilibrium and haplotype analyses in CYP1A1 and CYP1A2.
###end p 99
###begin p 100
(0.04 MB DOC)
###end p 100
###begin p 101
Click here for additional data file.
###end p 101
###begin p 102
Associations between SNPs and lung cancer overall and major histology subtypes.
###end p 102
###begin p 103
(0.79 MB DOC)
###end p 103
###begin p 104
Click here for additional data file.
###end p 104
###begin p 105
Joint SNP analysis.
###end p 105
###begin p 106
(0.05 MB DOC)
###end p 106
###begin p 107
Click here for additional data file.
###end p 107
###begin p 108
Haplotype and three-marker moving window analyses in EPHX1.
###end p 108
###begin p 109
(0.14 MB DOC)
###end p 109
###begin p 110
Click here for additional data file.
###end p 110
###begin p 111
Gene expression and SNP correlation analysis.
###end p 111
###begin p 112
(0.04 MB DOC)
###end p 112
###begin p 113
Click here for additional data file.
###end p 113
###begin p 114
Results for linkage disequilibrium and haplotype analyses in EPHX1 and CYP1B1.
###end p 114
###begin p 115
(0.03 MB DOC)
###end p 115
###begin p 116
Click here for additional data file.
###end p 116
###begin p 117
###xml 36 48 <span type="species:ncbi:9606">participants</span>
We are deeply indebted to the EAGLE participants and the study collaborators (listed in ).
###end p 117
###begin title 118
References
###end title 118
###begin article-title 119
Cancer statistics 2008.
###end article-title 119
###begin article-title 120
Early detection and prevention of lung cancer.
###end article-title 120
###begin article-title 121
Molecular epidemiology of lung cancer.
###end article-title 121
###begin article-title 122
Polymorphism of selected enzymes involved in detoxification and biotransformation in relation to lung cancer.
###end article-title 122
###begin article-title 123
Lung cancer susceptibility: are we on our way to identifying a high-risk group?
###end article-title 123
###begin article-title 124
Environment And Genetics in Lung cancer Etiology (EAGLE) study: an integrative population-based case-control study of lung cancer.
###end article-title 124
###begin article-title 125
The less harmful cigarette: a controversial issue. a tribute to Ernst L. Wynder.
###end article-title 125
###begin article-title 126
Metabolic activation of polycyclic aromatic hydrocarbons to carcinogens by cytochromes P450 1A1 and 1B1.
###end article-title 126
###begin article-title 127
###xml 60 65 <span type="species:ncbi:9606">human</span>
Metabolism of benzo[a]pyrene and benzo[a]pyrene-7,8-diol by human cytochrome P450 1B1.
###end article-title 127
###begin article-title 128
###xml 48 53 <span type="species:ncbi:9606">human</span>
Differential expression of CYP1A1 and CYP1B1 in human breast epithelial cells and breast tumor cells.
###end article-title 128
###begin article-title 129
###xml 56 61 <span type="species:ncbi:9606">human</span>
Phase I and II carcinogen metabolism gene expression in human lung tissue and tumors.
###end article-title 129
###begin article-title 130
Role of aryl hydrocarbon receptor-mediated induction of the CYP1 enzymes in environmental toxicity and cancer.
###end article-title 130
###begin article-title 131
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human CYP1A1 (cytochrome P(1)450) gene: lack of association between the Msp I restriction fragment length polymorphism and incidence of lung cancer in a Norwegian population.
###end article-title 131
###begin article-title 132
###xml 35 40 <span type="species:ncbi:9606">human</span>
A C4887A polymorphism in exon 7 of human CYP1A1: population frequency, mutation linkages, and impact on lung cancer susceptibility.
###end article-title 132
###begin article-title 133
CYP1A1 polymorphisms and lung cancer risk: a meta-analysis.
###end article-title 133
###begin article-title 134
Pooled analysis of the CYP1A1 exon 7 polymorphism and lung cancer (United States).
###end article-title 134
###begin article-title 135
Interaction of cytochrome P4501A1 genotypes with other risk factors and susceptibility to lung cancer.
###end article-title 135
###begin article-title 136
CYP1A1 and GSTM1 genotypes affect benzo[a]pyrene DNA adducts in smokers' lung: comparison with aromatic/hydrophobic adduct formation.
###end article-title 136
###begin article-title 137
###xml 90 95 <span type="species:ncbi:9606">human</span>
A common regulatory region functions bidirectionally in transcriptional activation of the human CYP1A1 and CYP1A2 genes.
###end article-title 137
###begin article-title 138
A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25.
###end article-title 138
###begin article-title 139
Lung cancer susceptibility locus at 5p15.33.
###end article-title 139
###begin article-title 140
The CHRNA5-A3 region on chromosome 15q24-25.1 is a risk factor both for nicotine dependence and for lung cancer.
###end article-title 140
###begin article-title 141
A variant associated with nicotine dependence, lung cancer and peripheral arterial disease.
###end article-title 141
###begin article-title 142
Common 5p15.33 and 6p21.33 variants influence lung cancer risk.
###end article-title 142
###begin article-title 143
Cytochrome P450 1B1 (CYP1B1) pharmacogenetics: association of polymorphisms with functional differences in estrogen hydroxylation activity.
###end article-title 143
###begin article-title 144
Characterization of common CYP1B1 variants with different capacity for benzo[a]pyrene-7,8-dihydrodiol epoxide formation from benzo[a]pyrene.
###end article-title 144
###begin article-title 145
Combinations of cytochrome P-450 genotypes and risk of early-onset lung cancer in Caucasians and African Americans: a population-based study.
###end article-title 145
###begin article-title 146
Association of functionally important polymorphisms in cytochrome P4501B1 with lung cancer.
###end article-title 146
###begin article-title 147
Association of CYP1B1 genetic polymorphism with incidence to breast and lung cancer.
###end article-title 147
###begin article-title 148
A comprehensive analysis of phase I and phase II metabolism gene polymorphisms and risk of non-small cell lung cancer in smokers.
###end article-title 148
###begin article-title 149
Mammalian epoxide hydrases: inducible enzymes catalysing the inactivation of carcinogenic and cytotoxic metabolites derived from aromatic and olefinic compounds.
###end article-title 149
###begin article-title 150
Epoxide hydrolases: biochemistry and molecular biology.
###end article-title 150
###begin article-title 151
Microsomal epoxide hydrolase. Properties, regulation and function.
###end article-title 151
###begin article-title 152
###xml 48 54 <span type="species:ncbi:9606">humans</span>
Distribution of microsomal epoxide hydrolase in humans: an immunohistochemical study in normal tissues, and benign and malignant tumours.
###end article-title 152
###begin article-title 153
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human microsomal epoxide hydrolase: genetic polymorphism and functional expression in vitro of amino acid variants.
###end article-title 153
###begin article-title 154
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human microsomal epoxide hydrolase: 5'-flanking region genetic polymorphisms.
###end article-title 154
###begin article-title 155
###xml 14 19 <span type="species:ncbi:9606">human</span>
Inhibition of human m-epoxide hydrolase gene expression in a case of hypercholanemia.
###end article-title 155
###begin article-title 156
EPHX1 polymorphisms and the risk of lung cancer: a HuGE review.
###end article-title 156
###begin article-title 157
###xml 110 118 <span type="species:ncbi:9606">patients</span>
Functional polymorphisms of the microsomal epoxide hydrolase gene: A reappraisal on a early-onset lung cancer patients series.
###end article-title 157
###begin article-title 158
EPHX1 gene polymorphisms and individual susceptibility to lung cancer.
###end article-title 158
###begin article-title 159
###xml 27 32 <span type="species:ncbi:9606">human</span>
Molecular modelling of the human cytochrome P450 isoform CYP2A6 and investigations of CYP2A substrate selectivity.
###end article-title 159
###begin article-title 160
Comprehensive evaluation of variability in nicotine metabolism and CYP2A6 polymorphic alleles in four ethnic populations.
###end article-title 160
###begin article-title 161
Genetic variation of CYP2A6, smoking, and risk of cancer.
###end article-title 161
###begin article-title 162
###xml 40 47 <span type="species:ncbi:4097">tobacco</span>
Genetic polymorphism of CYP2A6 gene and tobacco-induced lung cancer risk in male smokers.
###end article-title 162
###begin article-title 163
###xml 71 78 <span type="species:ncbi:4097">tobacco</span>
Genetic polymorphism of CYP2A6 as one of the potential determinants of tobacco-related cancer risk.
###end article-title 163
###begin article-title 164
Nicotine metabolism defect reduces smoking.
###end article-title 164
###begin article-title 165
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human neutrophil lipocalin (HNL) and myeloperoxidase (MPO). Studies of lung lavage fluid and lung tissue.
###end article-title 165
###begin article-title 166
###xml 84 89 <span type="species:ncbi:9606">human</span>
Activation of (+-)-trans-7,8-dihydroxy-7,8-dihydrobenzo[a]pyrene to diolepoxides by human polymorphonuclear leukocytes or myeloperoxidase.
###end article-title 166
###begin article-title 167
###xml 47 53 <span type="species:ncbi:9606">humans</span>
###xml 69 74 <span type="species:ncbi:9606">human</span>
Polymorphisms for aromatic amine metabolism in humans: relevance for human carcinogenesis.
###end article-title 167
###begin article-title 168
###xml 103 108 <span type="species:ncbi:9606">human</span>
Oxidant-dependent metabolic activation of polycyclic aromatic hydrocarbons by phorbol ester-stimulated human polymorphonuclear leukocytes: possible link between inflammation and cancer.
###end article-title 168
###begin article-title 169
Myeloperoxidase (MPO) -463G-->A reduces MPO activity and DNA adduct levels in bronchoalveolar lavages of smokers.
###end article-title 169
###begin article-title 170
Point: myeloperoxidase -463G-->a polymorphism and lung cancer risk.
###end article-title 170
###begin article-title 171
Counterpoint: the myeloperoxidase -463G-->a polymorphism does not decrease lung cancer susceptibility in Caucasians.
###end article-title 171
###begin article-title 172
Evidence for an intensity-dependent interaction of NAT2 acetylation genotype and cigarette smoking in the Spanish Bladder Cancer Study.
###end article-title 172
###begin article-title 173
Assessing the probability that a positive report is false: an approach for molecular epidemiology studies.
###end article-title 173
###begin article-title 174
Lung cancer susceptibility in relation to combined polymorphisms of microsomal epoxide hydrolase and glutathione S-transferase P1.
###end article-title 174
###begin article-title 175
Assessment of interactions between PAH exposure and genetic polymorphisms on PAH-DNA adducts in African American, Dominican, and Caucasian mothers and newborns.
###end article-title 175
###begin article-title 176
Genetic polymorphisms in CYP1B1, GSTA1, NQO1 and NAT2 and the risk of lung cancer.
###end article-title 176
###begin article-title 177
Rapid detection of single nucleotide polymorphisms related with lung cancer susceptibility of Chinese population.
###end article-title 177
###begin article-title 178
Gene expression signature of cigarette smoking and its role in lung adenocarcinoma development and survival.
###end article-title 178
###begin p 179
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests: </bold>
Competing Interests: The authors have declared that no competing interests exist.
###end p 179
###begin p 180
###xml 0 9 0 9 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding: </bold>
Funding: This study was supported by the Intramural Research Program of National Institutes of Health, National Cancer Institute, Division of Cancer Epidemiology and Genetics. AWB was supported by U01 DA020830. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
###end p 180

